ASA EFFECTS ON ANTIHYPERTENSIVE EFFICACIES OF ENALAPRIL AND LOSARTAN

本研究旨在研究81毫克和325毫克阿司匹林（ASA）对依那普利和氯沙坦个体降血压能力的影响。第二个目的是通过测量尿前列腺素浓度来表征ASA与氯沙坦或ASA与依那普利之间观察到的任何相互作用。原假设是，在依那普利或氯沙坦单药治疗方案中加入低剂量或平均剂量的ASA对血压没有影响。总共将招募18名受试者，每9名服用依那普利或氯沙坦。该研究包括一个3,2周的治疗期，分别使用ASA 81 mg， ASA 324 mg或安慰剂，每个治疗期间隔2周的洗脱期。通过袖带测压法收集坐位血压，完成12小时尿液收集并分析PGE2、PGE-M、6-酮- pgf1 α、2,3 dinor-PGI-M、TXB2和TX-M。血浆去甲肾上腺素浓度也将被收集。只有在安慰剂和asa治疗期间血压有统计学差异时，才进行尿液和血浆分析和比较。

This research is designed to study the effects of 81 mg and 325 mg of aspirin (ASA) on the individual abilities of enalapril and losartan to lower blood pressure. A secondary objective is to characterize any observed interaction between ASA and losartan or ASA and enalapril by measuring urinary prostanoid concentrations. The null hypothesis is that there is no difference in blood pressure when a low dose or average dose of ASA is added to a monotherapy regimen of either enalapril or losartan. A total of 18 subjects will be recruited, 9 each taking enalapril or losartan. The study involves a 3,2 week treatment periods with either ASA 81 mg, ASA 324 mg or placebo each separated by 2 week washout periods. Sitting BP will be collected via cuff manometry and 12-hour urine collections will be completed and analyzed for PGE2, PGE-M, 6-keto-PGF1alpha, 2,3 dinor-PGI-M, TXB2 and TX-M. Plasma norepinephrine concentrations will also be collected. Urine and plasma analyses and comparisons will only be performed if there is a statistical difference observed in blood pressure between the placebo and ASA-treatment periods.